CN117736297A - April和baff抑制性免疫调节蛋白及其使用方法 - Google Patents
April和baff抑制性免疫调节蛋白及其使用方法 Download PDFInfo
- Publication number
- CN117736297A CN117736297A CN202311249622.3A CN202311249622A CN117736297A CN 117736297 A CN117736297 A CN 117736297A CN 202311249622 A CN202311249622 A CN 202311249622A CN 117736297 A CN117736297 A CN 117736297A
- Authority
- CN
- China
- Prior art keywords
- taci
- amino acid
- seq
- polypeptide
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 358
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 354
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 253
- 238000000034 method Methods 0.000 title abstract description 60
- 230000002401 inhibitory effect Effects 0.000 title abstract description 15
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 121
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 121
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 572
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 553
- 229920001184 polypeptide Polymers 0.000 claims description 552
- 235000001014 amino acid Nutrition 0.000 claims description 463
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 371
- 238000006467 substitution reaction Methods 0.000 claims description 342
- 235000018102 proteins Nutrition 0.000 claims description 340
- 125000000539 amino acid group Chemical group 0.000 claims description 175
- 230000027455 binding Effects 0.000 claims description 156
- 230000009870 specific binding Effects 0.000 claims description 72
- 235000018417 cysteine Nutrition 0.000 claims description 32
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 30
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 29
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 9
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 24
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract description 136
- 150000007523 nucleic acids Chemical class 0.000 abstract description 69
- 102000039446 nucleic acids Human genes 0.000 abstract description 59
- 108020004707 nucleic acids Proteins 0.000 abstract description 59
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000003472 neutralizing effect Effects 0.000 abstract description 13
- 208000026278 immune system disease Diseases 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000012190 activator Substances 0.000 abstract description 4
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 abstract 3
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 abstract 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 170
- 150000001413 amino acids Chemical class 0.000 description 155
- 102220359928 c.229A>G Human genes 0.000 description 87
- 238000012986 modification Methods 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 86
- 239000012634 fragment Substances 0.000 description 86
- 230000004048 modification Effects 0.000 description 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 71
- 230000004927 fusion Effects 0.000 description 69
- 102200122316 rs121434582 Human genes 0.000 description 65
- 102200065463 rs1014454531 Human genes 0.000 description 63
- 102220595179 Casein kinase II subunit alpha'-interacting protein_F78W_mutation Human genes 0.000 description 62
- 210000003719 b-lymphocyte Anatomy 0.000 description 58
- 108060003951 Immunoglobulin Proteins 0.000 description 55
- 102000018358 immunoglobulin Human genes 0.000 description 55
- 102220359218 c.223C>G Human genes 0.000 description 44
- 230000035772 mutation Effects 0.000 description 40
- 208000035475 disorder Diseases 0.000 description 37
- 241000282414 Homo sapiens Species 0.000 description 35
- 201000010099 disease Diseases 0.000 description 34
- 108091006020 Fc-tagged proteins Proteins 0.000 description 32
- 230000001965 increasing effect Effects 0.000 description 32
- 230000028993 immune response Effects 0.000 description 31
- 239000003446 ligand Substances 0.000 description 31
- 238000012217 deletion Methods 0.000 description 29
- 230000037430 deletion Effects 0.000 description 29
- 102000005962 receptors Human genes 0.000 description 29
- 108020003175 receptors Proteins 0.000 description 29
- 239000000710 homodimer Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 230000003993 interaction Effects 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 102220631244 Interferon regulatory factor 6_R84G_mutation Human genes 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 102200035693 rs140005285 Human genes 0.000 description 20
- 239000012636 effector Substances 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 102000003390 tumor necrosis factor Human genes 0.000 description 18
- 239000013598 vector Substances 0.000 description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 102220539809 HLA class II histocompatibility antigen, DQ beta 1 chain_Y79F_mutation Human genes 0.000 description 14
- 239000000539 dimer Substances 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 102200143688 rs121434227 Human genes 0.000 description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 102220237632 rs1554721897 Human genes 0.000 description 13
- 102220188872 rs886053704 Human genes 0.000 description 13
- 208000023275 Autoimmune disease Diseases 0.000 description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 12
- 230000004936 stimulating effect Effects 0.000 description 12
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 12
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 11
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 102200118207 rs33936967 Human genes 0.000 description 10
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 102000018697 Membrane Proteins Human genes 0.000 description 9
- 108010052285 Membrane Proteins Proteins 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000024245 cell differentiation Effects 0.000 description 9
- 230000011748 cell maturation Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000001747 exhibiting effect Effects 0.000 description 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 102200033384 rs104893954 Human genes 0.000 description 9
- 102220138536 rs146905561 Human genes 0.000 description 9
- 102200131362 rs28928900 Human genes 0.000 description 9
- 102220166735 rs61747004 Human genes 0.000 description 9
- 102220276857 rs750878896 Human genes 0.000 description 9
- 102220183537 rs760971365 Human genes 0.000 description 9
- 102200140028 rs79555199 Human genes 0.000 description 9
- 102220083144 rs863224688 Human genes 0.000 description 9
- 102220130334 rs886045568 Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 8
- 239000000833 heterodimer Substances 0.000 description 8
- 229940050526 hydroxyethylstarch Drugs 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 102200019491 rs267608260 Human genes 0.000 description 8
- 102220072339 rs794728992 Human genes 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 description 7
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 235000004554 glutamine Nutrition 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 6
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 102000049398 Vasodilator-stimulated phosphoproteins Human genes 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 6
- 230000015861 cell surface binding Effects 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 102220082159 rs369666769 Human genes 0.000 description 6
- 102220207975 rs58272575 Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000035160 transmembrane proteins Human genes 0.000 description 6
- 108091005703 transmembrane proteins Proteins 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 102000056239 human TNFRSF13B Human genes 0.000 description 5
- 230000005965 immune activity Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004850 protein–protein interaction Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 4
- 101800000655 C-terminal peptide Proteins 0.000 description 4
- 102400000107 C-terminal peptide Human genes 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 description 4
- 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- -1 during cloning Chemical class 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000026872 Addison Disease Diseases 0.000 description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 3
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 3
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 3
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000001493 Cyclophilins Human genes 0.000 description 3
- 108010068682 Cyclophilins Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 208000031814 IgA Vasculitis Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010040628 Sialoadenitis Diseases 0.000 description 3
- 102220517225 Signal transducing adapter molecule 1_F77E_mutation Human genes 0.000 description 3
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 3
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 3
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 3
- 229960003270 belimumab Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000010001 cellular homeostasis Effects 0.000 description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000001050 sialadenitis Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000005829 trimerization reaction Methods 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229950009925 atacicept Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000001102 germinal center b cell Anatomy 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 102200070479 rs28933693 Human genes 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000793686 Homo sapiens Azurocidin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101100369999 Homo sapiens TNFSF13 gene Proteins 0.000 description 1
- 101100537522 Homo sapiens TNFSF13B gene Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100425947 Mus musculus Tnfrsf13b gene Proteins 0.000 description 1
- 101000830595 Mus musculus Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 1
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800001646 Protein n Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 101100174184 Serratia marcescens fosA gene Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001211 electron capture detection Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 101150078861 fos gene Proteins 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000006237 glutamylation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022373P | 2020-05-08 | 2020-05-08 | |
| US63/022,373 | 2020-05-08 | ||
| US202063034361P | 2020-06-03 | 2020-06-03 | |
| US63/034,361 | 2020-06-03 | ||
| US202063080643P | 2020-09-18 | 2020-09-18 | |
| US63/080,643 | 2020-09-18 | ||
| PCT/US2021/031430 WO2021226551A1 (en) | 2020-05-08 | 2021-05-07 | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| CN202180047833.1A CN115812077A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180047833.1A Division CN115812077A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117736297A true CN117736297A (zh) | 2024-03-22 |
Family
ID=76270049
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311249622.3A Pending CN117736297A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
| CN202310582491.4A Pending CN116903727A (zh) | 2020-05-08 | 2021-05-07 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
| CN202180047593.5A Pending CN116194467A (zh) | 2020-05-08 | 2021-05-07 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
| CN202411219401.6A Pending CN119258195A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
| CN202180047833.1A Pending CN115812077A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310582491.4A Pending CN116903727A (zh) | 2020-05-08 | 2021-05-07 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
| CN202180047593.5A Pending CN116194467A (zh) | 2020-05-08 | 2021-05-07 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
| CN202411219401.6A Pending CN119258195A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
| CN202180047833.1A Pending CN115812077A (zh) | 2020-05-08 | 2021-05-07 | April和baff抑制性免疫调节蛋白及其使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US12202882B2 (https=) |
| EP (2) | EP4146684A2 (https=) |
| JP (3) | JP7748393B2 (https=) |
| KR (2) | KR20230029621A (https=) |
| CN (5) | CN117736297A (https=) |
| AU (3) | AU2021268033A1 (https=) |
| BR (2) | BR112022022433A2 (https=) |
| CA (2) | CA3178885A1 (https=) |
| CL (1) | CL2022003104A1 (https=) |
| CO (1) | CO2022017780A2 (https=) |
| DK (1) | DK4146683T3 (https=) |
| FI (1) | FI4146683T3 (https=) |
| HR (1) | HRP20260229T1 (https=) |
| IL (2) | IL297981A (https=) |
| LT (1) | LT4146683T (https=) |
| MX (2) | MX2022013998A (https=) |
| PE (1) | PE20230494A1 (https=) |
| RS (1) | RS67815B1 (https=) |
| SI (1) | SI4146683T1 (https=) |
| TW (1) | TW202208414A (https=) |
| WO (2) | WO2021226553A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| KR20220034742A (ko) * | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| US20240301031A1 (en) * | 2021-03-31 | 2024-09-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Truncated taci polypeptide and fusion protein and use thereof |
| US20240279310A1 (en) * | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| KR20240053675A (ko) * | 2021-08-11 | 2024-04-24 | 악소 바이오파마슈티컬 인코포레이티드 | sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법 |
| JP2024538452A (ja) * | 2021-11-17 | 2024-10-21 | オーリニア・ファーマシューティカルズ・インコーポレイテッド | Ｂ細胞活性化因子（ｂａｆｆ）－増殖誘導リガンド（ａｐｒｉｌ）二重阻害剤 |
| EP4442702A4 (en) * | 2022-06-08 | 2025-12-31 | Remegen Co Ltd | METHOD FOR TREATMENT OF MYASTHENIA GRAVE WITH A TACI-FC FUSION PROTEIN |
| WO2024044721A1 (en) * | 2022-08-25 | 2024-02-29 | University Of Washington | Injectable recombinant protein-based hydrogels for therapeutic delivery |
| CN119698304A (zh) * | 2022-09-30 | 2025-03-25 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗膜性肾病的方法 |
| KR20250099778A (ko) * | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
| CN120435493A (zh) * | 2022-12-05 | 2025-08-05 | 阿雷克森制药公司 | 用于多功能抑制baff、april和新生儿fc受体的taci-fc融合蛋白 |
| AU2023387777A1 (en) * | 2022-12-07 | 2024-08-29 | Remegen Co., Ltd. | Taci-fc fusion protein liquid pharmaceutical preparation |
| CN121152636A (zh) * | 2023-07-06 | 2025-12-16 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法 |
| WO2025240392A1 (en) * | 2024-05-13 | 2025-11-20 | Paragon Therapeutics, Inc. | Fusion proteins |
| WO2026008004A1 (zh) * | 2024-07-04 | 2026-01-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法 |
Family Cites Families (298)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4644286A (en) | 1985-09-17 | 1987-02-17 | Allied Corporation | Article surveillance system receiver using synchronous demodulation and signal integration |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0584266B1 (en) | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| WO1996009380A1 (en) | 1994-09-23 | 1996-03-28 | The University Of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| DE69519521T2 (de) | 1994-10-03 | 2001-06-28 | The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| PT939804E (pt) | 1996-10-25 | 2005-11-30 | Human Genome Sciences Inc | Neutroquina alfa |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| WO2001060397A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US6375952B1 (en) | 1998-08-07 | 2002-04-23 | University Of Washington | Immunological herpes simplex virus antigens and methods for use thereof |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| SI1642972T1 (sl) * | 1999-01-07 | 2010-05-31 | Zymogenetics Inc | Terapevtske uporabe BR X topnih receptorjev |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| DK1218504T3 (da) | 1999-09-21 | 2007-11-12 | Genetics Inst Llc | GL50 molekyler og anvendelser deraf |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| AU2584901A (en) | 1999-12-22 | 2001-07-03 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| IL150571A0 (en) | 2000-01-03 | 2003-02-12 | Tr Associates L L C | Novel chimeric proteins and methods for using the same |
| GB2375113B (en) | 2000-01-21 | 2004-10-20 | Biovex Ltd | A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer |
| US20040013674A1 (en) | 2001-04-27 | 2004-01-22 | Christine Ambrose | Taci as an anti-tumor agent |
| DK1297013T3 (da) | 2000-04-27 | 2006-12-27 | Biogen Idec Inc | Anvendelse af TACI som antitumormiddel |
| EP1746106A3 (en) | 2000-04-27 | 2007-03-14 | Biogen Idec MA Inc. | Use of TACI as an anti-tumor agent |
| WO2001087977A2 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| CN101255192A (zh) | 2000-05-26 | 2008-09-03 | 布里斯托尔-迈尔斯斯奎布公司 | 可溶性ctla4突变体分子及其应用 |
| EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| EP1360290A2 (en) | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP1935427B1 (en) | 2000-07-03 | 2018-03-07 | Bristol-Myers Squibb Company | Uses of soluble CTLA4 mutant molecules |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| US7304033B2 (en) | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| EP1401870A4 (en) | 2001-05-24 | 2006-04-19 | Human Genome Sciences | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) |
| US7553939B2 (en) | 2001-06-29 | 2009-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes and methods of use thereof |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| BR0211614A (pt) | 2001-08-03 | 2006-10-31 | Genentech Inc | polipeptìdeo tacis e br3 e empregos dos mesmos |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CA2467521A1 (en) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| WO2004011611A2 (en) | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
| EP1553966B1 (en) | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| EP1558278B1 (en) | 2002-10-11 | 2009-09-02 | ZymoGenetics, Inc. | Production of homotrimeric fusion proteins |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| MXPA05006522A (es) | 2002-12-23 | 2006-02-17 | Bristol Myers Squibb Co | Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina. |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| JP2007526220A (ja) | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Ｂ細胞疾患の併用療法 |
| US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| ATE420160T1 (de) | 2003-06-18 | 2009-01-15 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| SG144925A1 (en) | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| JP2007509064A (ja) | 2003-10-20 | 2007-04-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｂａｆｆアンタゴニストのための治療養生法 |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| AU2005305182A1 (en) | 2004-11-04 | 2006-05-18 | Genentech, Inc. | Polypeptides that bind BAFF and/or APRIL |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| US7947805B2 (en) | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
| CN101120021A (zh) * | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| JP2008535841A (ja) | 2005-04-06 | 2008-09-04 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法 |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1922080A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
| WO2007019573A2 (en) * | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| AU2006281978A1 (en) | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
| JP2007103345A (ja) | 2005-09-07 | 2007-04-19 | Toyota Motor Corp | チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法 |
| EP1960525B1 (en) | 2005-09-09 | 2013-04-24 | Zymogenetics, Inc. | Method for preparing trimeric proteins |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| US8202698B2 (en) | 2005-11-08 | 2012-06-19 | Biogen Idec Ma Inc. | Methods of evaluating BAFF |
| DK1969007T3 (da) | 2005-12-20 | 2013-11-25 | Bristol Myers Squibb Co | Sammensætninger og fremgangsmåder til fremstilling af en sammensætning |
| BRPI0711823A2 (pt) * | 2006-05-15 | 2012-01-17 | Ares Trading Sa | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig |
| US8329162B2 (en) | 2006-07-21 | 2012-12-11 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| SI2061803T2 (sl) | 2006-08-28 | 2023-01-31 | Ares Trading S.A. | Postopek za čiščenje proteinov, ki vsebujejo FC |
| WO2008025747A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-fusion proteins |
| JP2010501622A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| ES2366593T3 (es) | 2007-01-26 | 2011-10-21 | Merck Serono S.A. | Purificación de proteínas de fusión taci-fc empleando la tecnología de cuerpos grasos. |
| CN101678106B (zh) | 2007-03-27 | 2013-06-05 | 津莫吉尼蒂克斯公司 | 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合 |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US20090186040A1 (en) | 2007-06-13 | 2009-07-23 | Busby Sharon J | DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-Ig FUSION PROTEIN SUCH AS ATACICEPT |
| CA2690627C (en) | 2007-06-15 | 2014-12-02 | Genelux Corporation | Microorganisms for imaging and/or treatment of tumors |
| CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| CN101784564B (zh) | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-dc变体 |
| JP2010533718A (ja) | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| HUE030134T2 (en) | 2007-10-16 | 2017-04-28 | Zymogenetics Inc | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases |
| WO2009053360A1 (en) | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an fc-containing protein |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| EP2612867A1 (en) | 2007-11-01 | 2013-07-10 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| DK2219675T3 (da) | 2007-11-12 | 2013-12-02 | Ares Trading Sa | Formuleringer for taci-immunglobulin-fusionsproteiner |
| CA2703545A1 (en) | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
| WO2009062926A1 (en) | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
| EP2225277A4 (en) | 2007-11-27 | 2012-03-14 | Viventia Biotech Inc | ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
| JP2011514160A (ja) | 2008-02-21 | 2011-05-06 | バーナム インスティテュート フォー メディカル リサーチ | Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物 |
| SG10202112838YA (en) | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
| HUE028784T2 (en) | 2008-05-01 | 2017-01-30 | Zymogenetics Inc | Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| US20120052003A9 (en) | 2008-05-16 | 2012-03-01 | Szalay Aladar A | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2010003766A2 (en) | 2008-06-17 | 2010-01-14 | Apogenix Gmbh | Multimeric tnf receptors |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| RU2515926C2 (ru) | 2009-02-04 | 2014-05-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца |
| WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| WO2010136480A1 (en) | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| ES2724451T3 (es) | 2010-02-04 | 2019-09-11 | Univ Pennsylvania | ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios |
| HUE030100T2 (en) | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| CN101851278B (zh) | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
| WO2011160086A2 (en) | 2010-06-18 | 2011-12-22 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system |
| WO2012032112A1 (en) | 2010-09-10 | 2012-03-15 | Cellerix, S.A. | Stem cell culture media and methods |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| CN102085368B (zh) | 2011-01-19 | 2013-06-12 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用 |
| EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| CN102836441B (zh) | 2011-06-24 | 2019-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| CN103796681B (zh) | 2011-06-30 | 2018-07-20 | 建新公司 | T细胞活化的抑制剂 |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| JP6355563B2 (ja) | 2012-02-27 | 2018-07-11 | アムニクス オペレーティング インコーポレイテッド | Ｘｔｅｎ共役組成物およびそれを製造する方法 |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| WO2013149167A1 (en) | 2012-03-30 | 2013-10-03 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| WO2013169338A1 (en) | 2012-05-11 | 2013-11-14 | Medimmune, Llc | Ctla-4 variants |
| US20130319861A1 (en) | 2012-05-30 | 2013-12-05 | Berkeley Lights, Inc. | Outputting A Droplet Of Liquid Medium From A Device For Processing Micro-Objects In The Medium |
| EP3202419A1 (en) | 2012-06-06 | 2017-08-09 | OncoMed Pharmaceuticals, Inc. | Pvrig binding agents that modulate the hippo pathway and uses thereof |
| KR20150033703A (ko) | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | 당뇨병 치료를 위한 ctla4 융합 단백질 |
| JP5857896B2 (ja) | 2012-07-06 | 2016-02-10 | 東京エレクトロン株式会社 | 成膜装置の運転方法及び成膜装置 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| CN103232542B (zh) * | 2013-02-01 | 2015-05-13 | 殷勇 | 一种双靶标嵌合蛋白 |
| WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| US10065987B2 (en) | 2013-02-12 | 2018-09-04 | Bristol-Myers Squibb Company | High pH protein refolding methods |
| US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| US20160271218A1 (en) | 2013-06-27 | 2016-09-22 | Mor Research Applications Ltd. | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| WO2015113494A1 (zh) | 2014-01-28 | 2015-08-06 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| US20170042972A1 (en) | 2014-04-25 | 2017-02-16 | Chetan KARYEKAR | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| US10562954B2 (en) * | 2014-05-12 | 2020-02-18 | Shanghai Kanda Biotechnology Co., Ltd. | Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| JP6652557B2 (ja) | 2014-05-30 | 2020-02-26 | ヴェンタナ メディカル システムズ， インク． | Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| EP3169363A4 (en) | 2014-07-16 | 2018-02-21 | F. Hoffmann-La Roche AG | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| PT3177640T (pt) | 2014-08-08 | 2020-08-31 | Univ Leland Stanford Junior | Agentes pd-1 de alta afinidade e métodos de utilização |
| EP3188752A2 (en) | 2014-09-03 | 2017-07-12 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| US20190119353A1 (en) | 2014-11-06 | 2019-04-25 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| WO2016118577A1 (en) | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
| HK1250637A1 (zh) | 2015-04-02 | 2019-01-11 | Cancure Limited | 用於引发免疫应答的剂和组合物 |
| CN121159719A (zh) | 2015-04-17 | 2025-12-19 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| HK1255161A1 (zh) | 2015-07-15 | 2019-08-09 | Juno Therapeutics, Inc. | 用於过继性细胞治疗的工程细胞 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017023749A1 (en) | 2015-07-31 | 2017-02-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
| CN108513576A (zh) | 2015-09-14 | 2018-09-07 | 高山免疫科学股份有限公司 | 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗 |
| TWI705972B (zh) | 2015-11-04 | 2020-10-01 | 臺北榮民總醫院 | 惡性病變的組合治療 |
| FI3380522T3 (fi) | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| WO2017201040A1 (en) | 2016-05-16 | 2017-11-23 | Berenson James Richard | Improved methods for monitoring immune status of a subject |
| CN109689096A (zh) | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| WO2018075978A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| CA3064632A1 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
| JP7385556B2 (ja) | 2017-09-01 | 2023-11-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| GB201720426D0 (en) | 2017-12-07 | 2018-01-24 | Hummingbird Bioscience Pte Ltd | CD47 and BCMA antigen-binding molecules |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| US20210238295A1 (en) | 2018-04-26 | 2021-08-05 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| CN110522908A (zh) | 2018-05-25 | 2019-12-03 | 荣昌生物制药（烟台）有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020028572A2 (en) | 2018-08-01 | 2020-02-06 | Unum Therapeutics Inc. | ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
| WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
| EP3853247A2 (en) | 2018-09-19 | 2021-07-28 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| MX2021012607A (es) | 2019-04-17 | 2022-03-11 | Alpine Immune Sciences Inc | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. |
| WO2020252421A2 (en) | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
| CN121930331A (zh) | 2019-09-13 | 2026-04-28 | 协和麒麟株式会社 | DcR3变体 |
| AU2020401160B2 (en) | 2019-12-10 | 2024-11-14 | Remegen Co., Ltd. | Pharmaceutical TACI-Fc fusion protein formulation |
| KR20220034742A (ko) | 2019-12-24 | 2022-03-18 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질 및 그 용도 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| PH12022553243A1 (en) | 2020-06-02 | 2024-02-12 | Ares Trading Sa | Methods related to the treatment of iga nephropathy |
| TW202220693A (zh) | 2020-08-12 | 2022-06-01 | 斯坦福大學托管董事會 | sBCMA變異體及其FC融合蛋白 |
| US20240279310A1 (en) | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| BR112023018745A2 (pt) | 2021-08-10 | 2024-03-12 | Remegen Co Ltd | Método para tratar nefropatia por iga com proteína de fusão de taci-fc |
| KR20240014066A (ko) | 2021-09-30 | 2024-01-31 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법 |
| EP4442702A4 (en) | 2022-06-08 | 2025-12-31 | Remegen Co Ltd | METHOD FOR TREATMENT OF MYASTHENIA GRAVE WITH A TACI-FC FUSION PROTEIN |
| KR20240030699A (ko) | 2022-08-31 | 2024-03-07 | 현대자동차주식회사 | 연료 전지 차량 |
| KR20250099778A (ko) | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
-
2021
- 2021-05-07 EP EP21730004.5A patent/EP4146684A2/en active Pending
- 2021-05-07 TW TW110116616A patent/TW202208414A/zh unknown
- 2021-05-07 US US17/315,168 patent/US12202882B2/en active Active
- 2021-05-07 CN CN202311249622.3A patent/CN117736297A/zh active Pending
- 2021-05-07 DK DK21730003.7T patent/DK4146683T3/da active
- 2021-05-07 FI FIEP21730003.7T patent/FI4146683T3/fi active
- 2021-05-07 KR KR1020227043139A patent/KR20230029621A/ko active Pending
- 2021-05-07 RS RS20260260A patent/RS67815B1/sr unknown
- 2021-05-07 KR KR1020227043140A patent/KR20230029622A/ko active Pending
- 2021-05-07 AU AU2021268033A patent/AU2021268033A1/en active Pending
- 2021-05-07 MX MX2022013998A patent/MX2022013998A/es unknown
- 2021-05-07 SI SI202130400T patent/SI4146683T1/sl unknown
- 2021-05-07 IL IL297981A patent/IL297981A/en unknown
- 2021-05-07 PE PE2022002607A patent/PE20230494A1/es unknown
- 2021-05-07 CN CN202310582491.4A patent/CN116903727A/zh active Pending
- 2021-05-07 AU AU2021267276A patent/AU2021267276B2/en active Active
- 2021-05-07 US US17/923,208 patent/US20230241168A1/en active Pending
- 2021-05-07 WO PCT/US2021/031432 patent/WO2021226553A2/en not_active Ceased
- 2021-05-07 CN CN202180047593.5A patent/CN116194467A/zh active Pending
- 2021-05-07 LT LTEPPCT/US2021/031430T patent/LT4146683T/lt unknown
- 2021-05-07 EP EP21730003.7A patent/EP4146683B1/en active Active
- 2021-05-07 HR HRP20260229TT patent/HRP20260229T1/hr unknown
- 2021-05-07 MX MX2022013999A patent/MX2022013999A/es unknown
- 2021-05-07 CN CN202411219401.6A patent/CN119258195A/zh active Pending
- 2021-05-07 CA CA3178885A patent/CA3178885A1/en active Pending
- 2021-05-07 BR BR112022022433A patent/BR112022022433A2/pt unknown
- 2021-05-07 CA CA3178882A patent/CA3178882A1/en active Pending
- 2021-05-07 WO PCT/US2021/031430 patent/WO2021226551A1/en not_active Ceased
- 2021-05-07 BR BR112022022524A patent/BR112022022524A2/pt unknown
- 2021-05-07 JP JP2022567473A patent/JP7748393B2/ja active Active
- 2021-05-07 IL IL297980A patent/IL297980A/en unknown
- 2021-05-07 CN CN202180047833.1A patent/CN115812077A/zh active Pending
- 2021-05-07 JP JP2022567472A patent/JP2023525032A/ja active Pending
- 2021-06-11 US US17/346,095 patent/US11274140B2/en active Active
-
2022
- 2022-11-08 CL CL2022003104A patent/CL2022003104A1/es unknown
- 2022-12-07 CO CONC2022/0017780A patent/CO2022017780A2/es unknown
-
2023
- 2023-03-17 US US18/186,098 patent/US12612447B2/en active Active
-
2024
- 2024-08-16 US US18/807,825 patent/US12304943B2/en active Active
- 2024-09-24 US US18/895,187 patent/US20250019412A1/en active Pending
- 2024-09-24 US US18/895,259 patent/US20250019413A1/en active Pending
-
2025
- 2025-01-22 AU AU2025200430A patent/AU2025200430A1/en active Pending
- 2025-06-19 JP JP2025103686A patent/JP2025134866A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12304943B2 (en) | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof | |
| US20240279310A1 (en) | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein | |
| JP2025535041A (ja) | 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質 | |
| HK40109407A (zh) | April和baff抑制性免疫调节蛋白及其使用方法 | |
| CN117915937A (zh) | 使用TACI-Fc融合免疫调节蛋白的给药和治疗方法 | |
| HK40090097A (zh) | April和baff抑制性免疫调节蛋白及其使用方法 | |
| HK40121599A (zh) | 使用taci-fc融合免疫调节蛋白的给药和治疗方法 | |
| HK40121598A (zh) | 使用taci-fc融合免疫调节蛋白的给药和治疗方法 | |
| HK40122392A (zh) | 使用taci-fc融合免疫调节蛋白的给药和治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40109407 Country of ref document: HK |